In the newly published paper “Biomimetic Remineralization of Carious Lesions by Self-Assembling Peptide” (J Dent Res; online 2017) Dr. Lucy Kind et al. present in detail the functionality of biomimetic regeneration with the CUROLOX® TECHNOLOGY
Using state of the art analytical methods like FTIR, µCT, MALDI-TOF, radioactive and fluorescence labeling the researchers show that the self-assembling peptide P11-4 as in CURODONTTM REPAIR, diffuses into the subsurface lesion, assembles into higher formed structures within the whole lesion volume, and facilitates nucleation of de novo hydroxyapatite crystals, resulting in increased mineral density within the subsurface carious lesion.
“The results prove that the application of self-assembling peptide P11-4 can facilitate the subsurface regeneration of the enamel lesion by supporting de novo mineralization and thus enabling a regenerative treatment of caries.” says Dr. Lucy Kind.
Link to article: “Biomimetic Remineralization of Carious Lesions by Self-Assembling Peptide”
CURODONTTM REPAIR is marketed in Switzerland under the brand name REGENAMEL®
About credentis ag
credentis ag is headquartered in Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Science Foundation (SNF), Aargauer Forschungsfonds and CTI in collaboration with the FHNW School of Life Sciences in Muttenz and the Medical Technologies IKC (in co-operation with the University of Leeds).
Dr. Dominik Lysek, CEO and Michael Hug, CTO have a strong track record in science, development and medical technology, with focus in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz, Gerard Moufflet and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.
Using state of the art analytical methods like FTIR, µCT, MALDI-TOF, radioactive and fluorescence labeling the researchers show that the self-assembling peptide P11-4 as in CURODONTTM REPAIR, diffuses into the subsurface lesion, assembles into higher formed structures within the whole lesion volume, and facilitates nucleation of de novo hydroxyapatite crystals, resulting in increased mineral density within the subsurface carious lesion.
“The results prove that the application of self-assembling peptide P11-4 can facilitate the subsurface regeneration of the enamel lesion by supporting de novo mineralization and thus enabling a regenerative treatment of caries.” says Dr. Lucy Kind.
Link to article: “Biomimetic Remineralization of Carious Lesions by Self-Assembling Peptide”
CURODONTTM REPAIR is marketed in Switzerland under the brand name REGENAMEL®
About credentis ag
credentis ag is headquartered in Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Science Foundation (SNF), Aargauer Forschungsfonds and CTI in collaboration with the FHNW School of Life Sciences in Muttenz and the Medical Technologies IKC (in co-operation with the University of Leeds).
Dr. Dominik Lysek, CEO and Michael Hug, CTO have a strong track record in science, development and medical technology, with focus in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz, Gerard Moufflet and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.
